Principal Financial Group Inc. Acquires 3,816 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Principal Financial Group Inc. raised its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 4.2% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 93,777 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,816 shares during the period. Principal Financial Group Inc. owned approximately 0.45% of ANI Pharmaceuticals worth $5,184,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in ANIP. State Street Corp lifted its position in ANI Pharmaceuticals by 9.1% during the third quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company’s stock valued at $41,991,000 after purchasing an additional 58,698 shares during the period. Pacer Advisors Inc. raised its stake in ANI Pharmaceuticals by 23,259.8% during the 3rd quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock valued at $33,907,000 after buying an additional 565,910 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of ANI Pharmaceuticals by 159.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock valued at $33,101,000 after buying an additional 340,854 shares during the period. Global Alpha Capital Management Ltd. boosted its stake in shares of ANI Pharmaceuticals by 1.8% in the 3rd quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock worth $32,005,000 after buying an additional 9,500 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of ANI Pharmaceuticals by 4.2% in the third quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company’s stock worth $25,373,000 after acquiring an additional 17,314 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Insider Activity

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the sale, the senior vice president now owns 49,059 shares in the company, valued at approximately $2,943,540. This represents a 2.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Stephen P. Carey sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the sale, the chief financial officer now directly owns 154,468 shares in the company, valued at approximately $8,617,769.72. This represents a 4.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,300 shares of company stock worth $584,009 in the last three months. Company insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Price Performance

NASDAQ ANIP opened at $58.46 on Tuesday. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $70.81. The stock has a market cap of $1.23 billion, a price-to-earnings ratio of -106.29 and a beta of 0.74. The company’s 50 day moving average is $57.23 and its two-hundred day moving average is $58.13.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ANIP. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. StockNews.com cut shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $77.71.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.